PDF herunterladen
Semin Thromb Hemost 2017; 43(06): 629-634
DOI: 10.1055/s-0037-1599146
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Clinical Significance of Antinuclear and Antiextractable Nuclear Antigen Antibody in Childhood Immune Thrombocytopenia

Qihui Liu
1   Department of Hematology and Oncology, Chongqing Key Laboratory of Pediatrics, Children's Hospital of Chongqing Medical University, Chongqing, China
,
Hongzhen Xu
1   Department of Hematology and Oncology, Chongqing Key Laboratory of Pediatrics, Children's Hospital of Chongqing Medical University, Chongqing, China
,
Xianmin Guan
1   Department of Hematology and Oncology, Chongqing Key Laboratory of Pediatrics, Children's Hospital of Chongqing Medical University, Chongqing, China
,
Yali Shen
1   Department of Hematology and Oncology, Chongqing Key Laboratory of Pediatrics, Children's Hospital of Chongqing Medical University, Chongqing, China
,
Xianhao Wen
1   Department of Hematology and Oncology, Chongqing Key Laboratory of Pediatrics, Children's Hospital of Chongqing Medical University, Chongqing, China
,
Yuxia Guo
1   Department of Hematology and Oncology, Chongqing Key Laboratory of Pediatrics, Children's Hospital of Chongqing Medical University, Chongqing, China
,
Jie Yu
1   Department of Hematology and Oncology, Chongqing Key Laboratory of Pediatrics, Children's Hospital of Chongqing Medical University, Chongqing, China
,
Yongchun Su
1   Department of Hematology and Oncology, Chongqing Key Laboratory of Pediatrics, Children's Hospital of Chongqing Medical University, Chongqing, China
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
25. April 2017 (online)

    Lizenzen und Reprints

Abstract

This study aims to determine the clinical significance of positive antinuclear/antiextractable nuclear antigen (ANA/A-ENA) antibody on manifestation and therapeutic response of childhood immune thrombocytopenia (ITP). Overall, 1,330 patients aged between 1 and 15.6 years diagnosed with primary ITP were retrospectively analyzed, excluding those with secondary ITP. Bleeding manifestations were recorded. All patients underwent autoantibody testing and follow-up for 32 months on average (range: 23–54 months). Steroid response was also assessed. Response rates were compared between ANA/A-ENA–positive and ANA/A-ENA–negative patients. Of all the patients enrolled, 84 tested positive only for ANA, 102 tested positive for A-ENA, 54 tested positive for both ANA and A-ENA, and 1,090 tested negative for both. Patients who were ANA/A-ENA positive were more likely to be female and older than 10 years. Patients who were A-ENA positive were more likely to have either persistent or chronic disease and suffer from life-threatening bleeding as well as poor short-term therapeutic response. We conclude that autoantibody testing is important to determine the short-term prognosis of ITP patients. Females, patients older than 10 years of age, and patients with either mixed positivity or A-ENA positivity should be more closely monitored.

Keywords

immune thrombocytopenia - antinuclear antigen - antiextractable nuclear antigen - childhood
 

  • References

  • 1 Rodeghiero F, Stasi R, Gernsheimer T. , et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113 (11) 2386-2393
    CrossrefPubMedSuche in Google Scholar
  • 2 Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. 1951. J Lab Clin Med 1990; 115 (05) 636-645
    PubMedSuche in Google Scholar
  • 3 Tomiyama Y, Kosugi S. Autoantigenic epitopes on platelet glycoproteins. Int J Hematol 2005; 81 (02) 100-105
    CrossrefPubMedSuche in Google Scholar
  • 4 Kashiwagi H, Tomiyama Y. Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol 2013; 98 (01) 24-33
    CrossrefPubMedSuche in Google Scholar
  • 5 Olsson B, Andersson PO, Jernås M. , et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9 (09) 1123-1124
    CrossrefPubMedSuche in Google Scholar
  • 6 Olsson B, Ridell B, Carlsson L, Jacobsson S, Wadenvik H. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 2008; 112 (04) 1078-1084
    CrossrefPubMedSuche in Google Scholar
  • 7 Chow L, Aslam R, Speck ER. , et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. Blood 2010; 115 (06) 1247-1253
    CrossrefPubMedSuche in Google Scholar
  • 8 Nishimoto T, Satoh T, Takeuchi T, Ikeda Y, Kuwana M. Critical role of CD4(+)CD25(+) regulatory T cells in preventing murine autoantibody-mediated thrombocytopenia. Exp Hematol 2012; 40 (04) 279-289
    CrossrefPubMedSuche in Google Scholar
  • 9 Yu J, Heck S, Patel V. , et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008; 112 (04) 1325-1328
    CrossrefPubMedSuche in Google Scholar
  • 10 Lippi G, Plebani M. EDTA-dependent pseudothrombocytopenia: further insights and recommendations for prevention of a clinically threatening artifact. Clin Chem Lab Med 2012; 50 (08) 1281-1285
    CrossrefPubMedSuche in Google Scholar
  • 11 Altintas A, Ozel A, Okur N. , et al. Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura. J Thromb Thrombolysis 2007; 24 (02) 163-168
    CrossrefPubMedSuche in Google Scholar
  • 12 Abbasi SY, Milhem M, Zaru L. A positive antinuclear antibody test predicts for a poor response to initial steroid therapy in adults with idiopathic thrombocytopenic purpura. Ann Hematol 2008; 87 (06) 459-462
    CrossrefPubMedSuche in Google Scholar
  • 13 Ktona E, Barbullushi M, Backa T, Idrizi A, Shpata V, Roshi E. Evaluation of thrombocytopenia in systemic lupus erythematosus and correlation with different organs damages. Mater Sociomed 2014; 26 (02) 122-124
    CrossrefPubMedSuche in Google Scholar
  • 14 Hazzan R, Mukamel M, Yacobovich J, Yaniv I, Tamary H. Risk factors for future development of systemic lupus erythematosus in children with idiopathic thrombocytopenic purpura. Pediatr Blood Cancer 2006; 47 (5, Suppl): 657-659
    CrossrefPubMedSuche in Google Scholar
  • 15 Aleem A, Al Arfaj AS, khalil N, Alarfaj H. Haematological abnormalities in systemic lupus erythematosus. Acta Reumatol Port 2014; 39 (03) 236-241
    PubMedSuche in Google Scholar
  • 16 Pratt EL, Tarantino MD, Wagner D, Hirsch Pescovitz O, Bowyer S, Shapiro AD. Prevalence of elevated antithyroid antibodies and antinuclear antibodies in children with immune thrombocytopenic purpura. Am J Hematol 2005; 79 (03) 175-179
    CrossrefPubMedSuche in Google Scholar
  • 17 Heitink-Pollé KM, Nijsten J, Boonacker CW, de Haas M, Bruin MC. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis. Blood 2014; 124 (22) 3295-3307
    CrossrefPubMedSuche in Google Scholar
  • 18 Imbach P, Kühne T, Müller D. , et al. Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer 2006; 46 (03) 351-356
    CrossrefPubMedSuche in Google Scholar
  • 19 Flores A, Buchanan GR. Bleeding severity as an important outcome in childhood immune thrombocytopenia. Pediatr Blood Cancer 2013; 60 (Suppl. 01) S8-S11
    CrossrefPubMedSuche in Google Scholar
  • 20 Grainger JD, Rees JL, Reeves M, Bolton-Maggs PH. Changing trends in the UK management of childhood ITP. Arch Dis Child 2012; 97 (01) 8-11
    CrossrefPubMedSuche in Google Scholar